January 17, 2023 – Study: Stomach Cancer Increases Among Younger Americans

The rate of stomach cancer is increasing among Americans under 50, particularly women, according to a study by the National Cancer Institute. Researchers tracked the incidence of lower stomach cancer in the United States. Mercy Medical Center surgical oncologist Dr. Vadim Gushchin said the incidence of gastric cancer is very low in the U.S. and…

Read More

January 2, 2023 – Zolbetuximab and Chemotherapy Combination Demonstrates Positive Results for Some Patients with Gastric Cancers, According to Results from Phase 3 Trial

Zolbetuximab in combination with a chemotherapy regimen including capecitabine and oxaliplatin (CAPOX) demonstrated positive results in patients with HER2-negative locally advanced unresectable or metastatic gastric and gastroesophageal junction cancers, according to results of GLOW, a phase 3 clinical trial. Read more>

Read More

December 22, 2022 – Associations Between CDH1 Germline Variants and Hereditary Diffuse Gastric Cancer Syndrome Cancer Phenotypes

In a study reported in The Lancet Oncology, Garcia-Pelaez and colleagues found that presence of germline truncating pathogenic variants or likely pathogenic variants of CDH1 were associated with hereditary diffuse gastric cancer (HDGC) tumor risk syndrome–related cancer phenotypes (lobular breast cancer, diffuse gastric cancer, and gastric cancer), with no apparent association of these phenotypes with CDH1 missense variants of unknown…

Read More

December 19, 2022 – Enhertu Approved in the EU for Patients with Previously Treated HER2-Positive Advanced Gastric Cancer

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. Enhertu is a specifically engineered HER2-directed antibody-drug conjugate (ADC) being jointly developed and commercialised by AstraZeneca and Daiichi…

Read More

December 9, 2022 – SCIENTIFIC PEER REVIEW OF CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS’ PEER REVIEWED CANCER RESEARCH PROGRAM FOR THE DEPARTMENT OF DEFENSE

Re: Consumer Participation on Scientific Peer Review Panels  For Immediate Press Release:  SCIENTIFIC PEER REVIEW OF CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS’ PEER REVIEWED CANCER RESEARCH PROGRAM FOR THE DEPARTMENT OF DEFENSE The Congressionally Directed Medical Research Programs’ (CDMRP), Peer Reviewed Cancer Research Program (PRCRP) consumer advocate Amy Jacobs recently participated in the evaluation of research…

Read More